MELK and triple-negative breast carcinoma: Studies have shown that MELK is a novel biomarker and a potential therapeutic target in cervical cancer (Lv et al., 2018), triple-negative breast cancer (Moreno, 2016) and gastric cancer (Zhang et al., 2016a).